Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry

Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years

Picks, perils and predictions for biopharma in 2025 — the latest BioCentury podcast

Two more studies of navacaprant underway as company considers possible female-only effect

Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question

Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia

Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena

From subjective symptoms to objective metrics to biological signatures, neuroscience head Bill Martin paints a trajectory of psychiatry’s path ahead 

BioCentury’s analysts look back at a year when innovation was hot but markets were not, and predict what’ll make news in 2024

As a pair of biotechs raise a combined $540M in NASDAQ offerings, how have other listings in the sector fared in the aftermarket this year?